Simplify Health Care ETF

Shares for the Cure

Introducing PINK - Simplify Health Care ETF. The first ETF committed to donating all net profits* to the Susan G. Komen breast cancer organization.


One in eight women will be diagnosed with breast cancer at some point in her lifetime. Funding research to find the cures is an incredible challenge that demands significant financial resources. That’s why Simplify chose Susan G. Komen as our beneficiary for this product, which we believe can enable you, the investor, to grow your portfolio while simultaneously helping a worthy cause.


PINK is an exchange traded fund (ETF) focused on the healthcare and biotech sectors. PINK combines the active stock selection, rigorous company and industry research, and due diligence processes of a hedge fund, with the daily liquidity, low cost, and tax efficiencies of an ETF. The fund is actively managed by renowned hedge fund investor Michael Taylor, who brings over two decades of healthcare and biotech investment experience.

About Susan G. Komen


About Susan G. Komen

Since 1982, Susan G. Komen has led the fight against breast cancer through a powerful combination of research, community health programs, and public policy initiatives. We are thrilled to announce our new relationship with Simplify ETFs.

learn more

A Competitive Solution to the Rapidly Growing Healthcare & Biotech Sectors

Simplify Health Care ETF provides investors with enhanced exposure to healthcare and biotech markets. All of Simplify’s net profits* earned from managing the Fund will be donated to Susan G. Komen. Through this donation Simplify will help create a significant contribution in the fight against breast cancer.

*With a guaranteed minimum of $100,000 annually.

About Michael Taylor

Michael Taylor

About Michael Taylor

Michael Taylor is a Portfolio Manager and Managing Director of CriticalMass Partners LLC (2011-2019), specializing in Healthcare Investing. For the past two decades, he managed hedged and factor neutral-portfolios with a gross amount over $1billion at funds including Millennium, Citadel and Diamondback Capital. Michael is regarded to have built and run one of the best-performing Healthcare funds on Wall Street. He began his investment career at OppenheimerFunds as the Head of Healthcare. He has overseen the day to day operations, portfolio selection/trades and research staff. Previous to Portfolio Management, Michael worked as a Scientist during the 1990's developing predominantly Viral-vector based Gene Therapeutic Drugs for the Bio/Pharma industry. Michael holds advanced degrees in Science and Business from the Johns Hopkins University and the William E. Simon School of Business.

Investing for Cures: Q&A with Michael Taylor
Keeping it Simple: Finding Alpha and Fighting for Cures

About Simplify

Simplify ETFs was established with the idea of democratizing access to investment strategies traditionally only available to institutions and accredited investors. Its focus is to disrupt modern asset allocation through harnessing the power of convexity.

learn more